We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Kimberly-Clark
KMB
$37.6B
| $29M | 0.05% |
287,841
+47,269
| +20% | +$5.17M |
|
327
Mettler-Toledo International
MTD
$28.1B
| $28.9M | 0.04% |
20,756
+2,862
| +16% | +$4M |
|
328
Brixmor Property Group
BRX
$9.72B
| $28.8M | 0.04% |
1,099,253
+12,953
| +1% | +$342K |
|
329
Southern Copper
SCCO
$138B
| $28.7M | 0.04% |
204,005
-157,124
| -44% | -$20.8M |
|
330
Otis Worldwide
OTIS
$27.9B
| $28.5M | 0.04% |
326,398
-7,078
| -2% | -$633K |
|
331
Viavi Solutions
VIAV
$7.95B
| $28.5M | 0.04% |
1,598,687
+13,936
| +0.9% | +$225K |
|
332
Entergy
ETR
$50.3B
| $28.1M | 0.04% |
304,089
-1,106
| -0.4% | -$105K |
|
333
Waters Corp
WAT
$37.3B
| $28.1M | 0.04% |
73,863
-2,721
| -4% | -$1M |
|
334
Microchip Technology
MCHP
$38.8B
| $27.5M | 0.04% |
430,962
+10,731
| +3% | +$662K |
|
335
Expedia Group
EXPE
$36.5B
| $27.1M | 0.04% |
95,724
-954
| -1% | -$236K |
|
336
Alphatec Holdings
ATEC
$1.48B
| $27.1M | 0.04% |
1,286,195
+294,792
| +30% | +$5.46M |
|
337
Paychex
PAYX
$43.4B
| $26.9M | 0.04% |
239,560
-7,355
| -3% | -$861K |
|
338
Republic Services
RSG
$67.4B
| $26.9M | 0.04% |
126,739
-6,149
| -5% | -$1.32M |
|
339
Flutter Entertainment
FLUT
$18.7B
| $26.8M | 0.04% |
124,851
-1,338
| -1% | -$301K |
|
340
Arch Capital
ACGL
$35.7B
| $26.6M | 0.04% |
277,789
-28,289
| -9% | -$2.59M |
|
341
Sun Communities
SUI
$15.8B
| $26M | 0.04% |
210,110
+320
| +0.2% | +$40.1K |
|
|
XYZ
342
Block Inc
XYZ
$48.9B
| $26M | 0.04% |
399,551
-3,010
| -0.7% | -$208K |
|
343
Camden Property Trust
CPT
$11.5B
| $25.9M | 0.04% |
235,525
-33,468
| -12% | -$3.48M |
|
344
Kroger
KR
$36.7B
| $25.9M | 0.04% |
414,587
+21,662
| +6% | +$1.42M |
|
345
Personalis
PSNL
$1.25B
| $25.9M | 0.04% |
3,249,895
+861,948
| +36% | +$7.54M |
|
346
NewAmsterdam Pharma
NAMS
$3.26B
| $25.6M | 0.04% |
729,484
+67,538
| +10% | +$2.46M |
|
347
Royalty Pharma
RPRX
$26.2B
| $25.6M | 0.04% |
661,416
+98,191
| +17% | +$3.74M |
|
348
Steris
STE
$22.9B
| $25.4M | 0.04% |
100,088
+20,097
| +25% | +$5.05M |
|
349
Tractor Supply
TSCO
$16.3B
| $25.3M | 0.04% |
506,779
+33,367
| +7% | +$1.8M |
|
350
SharkNinja
SN
$22.5B
| $25.3M | 0.04% |
226,097
-31,098
| -12% | -$3.06M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.